MDGL
Time to buy MDGL?$497.27
$-18.69 (-3.62%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
MDGL ran from roughly $420 in late October 2025 to its $615 52 week high in late December as Rezdiffra sales traction and Europe approval momentum kept the MASH story hot.
The stock has the potential to go down if it loses $490, with a retrace toward the $450 to $420 range possible. Any slowdown in Rezdiffra uptake, heavier spending on pipeline deals, or weak guidance would accelerate the downside.
If MDGL holds the $490 to $500 area, a move back toward $550 to $615 is on the table. Resistance at $530 is the first hurdle, and strong Rezdiffra sales follow-through or fresh pipeline updates could help.
Analyst Ratings
Madrigal Pharmaceuticals Inc. Earnings
We don't currently have information about Madrigal Pharmaceuticals Inc.'s earnings.